Vasilisa Yu. Terekhina

Vasilisa Yu. Terekhina

Auto-generated profile, based on publicly available information

Vasilisa Yu. Terekhina

Altai State Medical University, Health Ministry of Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Bulletin of Medical Science
Verified
Journal Article
Closed access
VTV.Yu. Terekhina
V.Yu. Terekhina
МНМария Геннадьевна Николаева
Мария Геннадьевна Николаева
AMAndrey Momot
Andrey Momot
AKA.V. Kudinov
A.V. Kudinov
ESE.V. Stroganova
E.V. Stroganova
DBD.S. Bublikov
D.S. Bublikov

3 September 2021 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
МНМария Геннадьевна Николаева
Мария Геннадьевна Николаева
VТVasilisa U. Тerekhina
Vasilisa U. Тerekhina
AKAlexey V. Kudinov
Alexey V. Kudinov
AMAndrey Momot
Andrey Momot
Pre-eclampsia is a clinically unfavorable pregnancy outcome that determines the main indicators of maternal and/or perinatal morbidity and mortality. According to modern concepts, the placenta plays a central role in the development of PE, while intercellular and intervesicular communications involving extracellular vesicles (EVs, extracellular vesicles) initiate a cascade of various biological effects, determining the mechanisms of ontogenesis of the gestational process in normal and pathological conditions. Achievements in studies of extracellular vesicles (EVs, extracellular vesicles) are of particular interest both to clinicians and to researchers studying the pathophysiology of gestational complications. Extracellular vesicles (EVs) in preeclampsia are produced both by scintiotrophoblast and the maternal body - blood cells (platelets, red blood cells, white blood cells) and the cardiovascular (vascular endothelium, smooth muscle) system. Changes in the concentration of these EVs can contribute to the implementation of preeclampsia, enhancing the pro-inflammatory and procoagulant states inherent in the gestation process. This review focuses on freely available information on the possible interactions between placental and maternal EVs. Understanding the contribution of EVs to the development of preeclampsia can help to deepen knowledge about the pathogenesis of this pathology and determine the diagnostic and prognostic significance of extracellular vesicles as biomarkers.

1 January 2020 in Siberian Medical Review
Verified
Journal Article
Closed access
AUAltai state medical University
Altai state medical University
ISI.S. Stepanova
I.S. Stepanova
VTV.YU. Terekhina
V.YU. Terekhina
The aim of the work is to study clinical cases and outcomes of pregnancy in women who have pelvic fracture during pregnancy. The article examines two cases of concomitant injury in pregnant patients at 25-37 weeks. In both cases, there is a break of pelvic bones of various localization. On basis of these observations, the authors draw conclusions about the significance of the mother’s condition and associated injuries for a favorable outcome.

15 August 2023 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
МНМария Геннадьевна Николаева
Мария Геннадьевна Николаева
VTV. Yu. Terekhina
V. Yu. Terekhina
AKA. V. Kudinov
A. V. Kudinov
ISI. I. Shakhmatov
I. I. Shakhmatov
AMAndrey Momot
Andrey Momot
Aim: to assess the blood level of biological endothelial damage markers in women with previous early-onset preeclampsia (еPE) during both the preconception (PC) stage and the first trimester of pregnancy.Materials and Methods. A prospective single-center cohort study was conducted. The control group comprised 40 women with uncomplicated pregnancies. The observation group consisted of 97 patients with a history of ePE, stratified based on pregnancy outcome into the comparison group (n = 59) characterized by a favorable gestational course, and the main group (n = 38) with relapsed еPE (30 patients were excluded from the study). Markers of systemic endotheliosis were determined in women at the PC stage and at 11–13 weeks of gestation: endothelin-1 (ET-1) and endothelial extracellular vesicles (EVs; CD-144).Results. At the PC stage, women in the control group and patients from the comparison group had comparable median (Me) ET-1 levels – 0.39 and 0.40 pmol/ml (p = 0.5935), respectively; at the same time, patients with relapsed еPE vs. control group had it significantly elevated (Me = 0.55 pmol/ml; p = 0.0382). At gestational age of 11–13 weeks, ET-1 level was significantly higher in the group with relapsed еPE (Me = 0.93 pmol/ml) than in control group (Me = 0.29 pmol/ml; p < 0.0001) and comparison group (Me = 0.42 pmol/ml; p = 0.0003). No significant changes in E-EVs (CD-144) level at various PС stages were observed, whereas in the study groups such parameters remained differed.Conclusion. Biological markers evidencing about systemic endothelial dysfunction/destruction – ET-1 and E-EVs (CD-144) in patients with previous ePE can be considered as predictive tests of disease relapse with an accuracy of 63.5 % and 83.0 % at the PС stage and 85.7 % and 94.2 % at gestational age of 11–13 weeks, respectively.

27 June 2022 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
МНМария Геннадьевна Николаева
Мария Геннадьевна Николаева
KSK. V. Shchekleina
K. V. Shchekleina
AMAndrey Momot
Andrey Momot
VTV. Yu. Terekhina
V. Yu. Terekhina
EGE. V. Grigorieva
E. V. Grigorieva
Aim: to determine a role of specific parameters of coagulation hemostasis for development of severe early-onset preeclampsia (еPE) in low-risk patients.Materials and Methods. A single-center prospective study included 40 patients with a physiological course of pregnancy and term delivery (control group) as well as 41 pregnant women with developed severe еPE (study group). Patients at the gestational age of 19–21 and 27–28 weeks in the comparison groups were examined for serum tissue factor (TF) activity; tissue factor pathway inhibitor (TFPI) and potential to generate thrombin in calibrated thrombography test.Results. Patients with developed ePE vs. control group were found to have significantly increased TF activity at both time points: 49.1 pmol/ml vs. 5.3 pmol/ml (p < 0.0001) and 56.7 pmol/ml vs. 6.6 pmol/ml (p < 0.0001); respectively. At gestational age of 19–21 weeks; patients in the study vs. control group had serum TFPI level significantly lower (1.1 U/ml vs. 1.6 U/ml; p < 0.0001) that was significant elevated up to 2.1 U/ml by 82 % at 27–28 weeks of pregnancy. At both time points; a significantly increased thrombin generation was detected in women with developed ePE.Conclusion. The development of ePE is characterized by increased potential to generate thrombin. TF has been identified as a more sensitive marker of activated coagulation hemostasis; and its significantly increased activity was recorded at gestational age of 19–21 weeks that allows us to consider TF as a prognostic biomarker.

4 January 2023 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
МНМария Геннадьевна Николаева
Мария Геннадьевна Николаева
VTV. Yu. Terekhina
V. Yu. Terekhina
AMAndrey Momot
Andrey Momot
Aim: to study the contribution of maternal blood endothelial proteins to developing relapse of early preeclampsia (ePE).Materials and Methods. A proteomic analysis of the peripheral blood of 137 pregnant women was performed. Clinically, three groups were identified at the end of pregnancy: control (n = 40), patients with favorable course of the current and previous pregnancy; comparison group (n = 59) – patients with a history of еPE episode, but favorable course of ongoing pregnancy, and main group (n = 38) – patients with еPE relapse. Biologically active substances evidencing about impaired endothelial function were subject to dynamic monitoring (11–13, 19–21 and 27–28 weeks): activity of endothelin-1 (ET-1) and metalloproteinase ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), von Willebrand factor (vWF) level and homocysteine (HC) concentration. The ADAMTS-13/vWF ratio was evaluated separately.Results. For patients with recurrent еPE, a significant increase in ET-1 is characteristic at all stages of gestation: 0.92; 1.07 and 1.36 pmol/ml vs. 0.29; 0.33 and 0.29 pmol/ml in the control group (p < 0.0001 at all points). Regardless of pregnancy outcome, increasing gestational age was paralleled with elevating vWF level, however, upon еPE relapse, this parameter (Me = 343 IU) is significantly higher (p < 0.0001) than in control group (Me = 260 IU). In all groups, there was a significant decrease in ADAMTS-13 activity, whereas in main group ADAMTS-13 activity at first time point was minimal – 63.4 % (p = 0.0007 relative to control group). With regard to ADAMTS-13/vWF axis in relapsed еPE, significant differences were found compared with control group both at 11–13 weeks (0.32 vs. 0.52; p < 0.0001) and at 27–28 weeks (0.15 vs. 0.22; p < 0.0001) pregnancy. The HC concentration declines with gestational age, but at first time point patients from main group had it (Me = 8.0 µmol/L) at significantly higher level than in control group (Me = 5.9 µmol/L; p < 0.00010).Conclusion. At gestational age of 11–13 weeks, all analyzed biomarkers contribute to developing еPE relapse accounting for an overall impact of 62.3 % of developing ePE risk. During pregnancy at 19–21 weeks, an imbalance in the ADAMTS-13/vWF along with elevated ET-1 level determine the risk of disease relapse in 65.6 % of cases. It was found that at a gestational age of 27–28 weeks, the associated shift in ET-1, vWF and ADAMTS-13 magnitude accounts for 67.9 % of risk for disease relapse.